GuidelineClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2025).
Guideline in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Total neoadjuvant therapy for locally advanced rectal cancer in Spain: results from a national patterns-of-care survey by the SEOR-GI Group.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This guideline provides a comprehensive overview of the management of localized rectal cancer, highlighting recent major advances in therapeutic strategies. Accurate staging remains essential, as it informs treatment decisions and facilitates risk assessment. A pivotal development in rectal cancer treatment is the adoption of total neoadjuvant therapy (TNT), which has demonstrated improved tumor response, reduced risk of systemic recurrence, and enhanced survival outcomes. This approach enables a "watch-and-wait" strategy and conservative management that may render surgery unnecessary and preserves rectal function in patients who achieve a complete clinical response. By emphasizing a structured approach to staging, multidisciplinary evaluation, and innovative treatment pathways, this guideline aims to improve outcomes while minimizing the morbidity associated with rectal cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.